Cardiff Oncology, Inc.
CRDF
$1.53
$0.032.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 41.00K | 243.00K | 120.00K | 121.00K | 109.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 41.00K | 243.00K | 120.00K | 121.00K | 109.00K |
| Cost of Revenue | 6.77M | 5.08M | 8.20M | 11.58M | 10.48M |
| Gross Profit | -6.72M | -4.83M | -8.08M | -11.46M | -10.37M |
| SG&A Expenses | 6.13M | 3.00M | 3.90M | 3.32M | 4.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.89M | 8.07M | 12.09M | 14.90M | 14.49M |
| Operating Income | -12.85M | -7.83M | -11.97M | -14.78M | -14.38M |
| Income Before Tax | -12.35M | -7.22M | -11.26M | -13.94M | -13.43M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.35M | -7.22M | -11.26M | -13.94M | -13.43M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.35M | -7.22M | -11.26M | -13.94M | -13.43M |
| EBIT | -12.85M | -7.83M | -11.97M | -14.78M | -14.38M |
| EBITDA | -12.76M | -7.74M | -11.89M | -14.68M | -14.29M |
| EPS Basic | -0.18 | -0.11 | -0.17 | -0.21 | -0.20 |
| Normalized Basic EPS | -0.11 | -0.07 | -0.11 | -0.13 | -0.13 |
| EPS Diluted | -0.18 | -0.11 | -0.17 | -0.21 | -0.20 |
| Normalized Diluted EPS | -0.11 | -0.07 | -0.11 | -0.13 | -0.13 |
| Average Basic Shares Outstanding | 68.35M | 67.43M | 66.88M | 66.53M | 66.52M |
| Average Diluted Shares Outstanding | 68.35M | 67.43M | 66.88M | 66.53M | 66.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |